# Onconetix

Source: https://onco.cc/companies/onconetix/  
OnCo record `onconetix` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Onconetix is a Cincinnati company that owns Proclarix, a blood test that helps decide whether a man with an unclear PSA result needs a prostate biopsy. The test is sold in Europe.

## Summary

Onconetix, Inc., of Cincinnati, was incorporated in October 2018 and acquired Proteomedix AG in December 2023, gaining Proclarix, a protein-based blood test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. The company expects Proclarix to be marketed in the United States as a laboratory-developed test under a licence to Labcorp. It abandoned commercialisation of ENTADFI, a finasteride and tadalafil pill for benign prostatic hyperplasia, and no longer holds inventory.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Onconetix, Inc.; Proteomedix AG
- HQ: Cincinnati, OH
- Type: diagnostics
- Website: https://www.onconetix.com/
- Ticker: ONCO

## Notes

- Read on 4 November 2026 in the S-1/A filed with the SEC on 31 August 2026. The filing does not give the year of European approval.

## Sources

- SEC: Onconetix Form S-1/A, August 2026: https://www.sec.gov/Archives/edgar/data/1782107/000121390026095703/ea0303846-s1a1_onconetix.htm
- Official website: https://www.onconetix.com/

## Connected records

- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [PSA and MRI-first prostate cancer screening](https://onco.cc/technologies/prostate-screening-psa-mri/)
- drugs: [Proclarix](https://onco.cc/drugs/proclarix/)

---
JSON: https://onco.cc/api/v1/entities/onconetix.json